Mycobacterium tuberculosis (TB) is among the most common of infectious diseases that cause death, and as many as one-third of the world's population may be infected. This work presents 17 novel hydrazide agents formed by focused in silico data mining utilizing search parameters restricted to substituent replacement only. Substituent substitution has been highly successful in design of novel antibacterial and antiviral drugs. This diverse set of hydrazide constructs possess molecular properties indicating favorable bioavailability with excellent intestinal absorption for oral administration. All agents have zero violations of the Rule of 5, indicating favorable druglikeness. Important pharmaceutical properties including polar surface area, Log P, and formula weight were determined and compared to that of the parent structure of isoniazid by hierarchical cluster analysis and discriminant analysis. The average Log P with range is -0.258 and -2.165 to 1.373, respectively. The average polar surface area (PSA) with range is 75.19 A 2 and 55.121 A 2 to 94.036 A 2 , respectively. The diverse range of PSA and Log P, with other descriptors, portend a versatile group of hydrazide drugs having substantial potential to expand the application and effectiveness forclinical treatment of multi-organ infected TB patients. Analysis of similarity indicated that all 17 agents are significantly similar to isoniazid, however discriminant analysis and hierarchical cluster analysis are able to differentiate isoniazid based upon molecular properties. Molecular weight and number of atoms were highly correlated by Pearson r (r>0.9000), with Log P moderately correlated (r>0.5500) to number of atoms, molecular weight, and volume. Seventeen hydrazide compounds (success rate of approximately 38%) having diverse pharmaceutical properties resulted from substituent data mining with potential for clinical application.
Introduction
Mycobacterium tuberculosis (TB, tubercle bacillus) is a type of mycobacteria that causes a common and dangerous infectious disease in humans, which usually attacks the lungs. 1, 2 Saliva of infected individuals transmitted by cough, sneeze, sputum, or other methods spreads the infectious bacteria. 2 Although generally associated with a pulmonary locality, the bacillus can infect other organs of the body and cause a broad range of symptoms. It is generally believed that up to one-third of the world's population is infected with TB. 3 Infections of other organs can co-exist with a pulmonary located TB, however 75% of all cases involve infection of the lungs. 4 The high lipid content within the cell wall of this microbe contributes to the unique clinical features of this pathogen. 5 In itself Mycobacterium tuberculosis is a small aerobic non-motile bacillus classified as a gram-positive bacterium, and is able to survive in dry states for weeks (which can exacerbate the infectious propensity), and is able to withstand weak disinfectants. Other TB causing mycobacterium that comprise the Mycobacterium tuberculosis complex include: M. africanum (a significant problem in some parts of Africa), M. canetti (which is observed in Africa), M. microti (observed in immunodeficient patients), and M. bovis (which has been reduced through pasteurization of milk). 6 TB is among the top three infectious killer diseases (malaria, HIV, TB) with several million new cases of TB take place every year. 7 The global resurgence of TB and rapid emergence of multi-drug resistant TB (MDR-TB) accentuates the need for development of new antituberculosis compounds. The investigation of new pharmaceutics to content with MDR-TB is urgently necessitated. 7 Previous studies have shown that 1.6% of global new cases of TB are MDR-TB, and in 2006 as much as 50% of new cases occurring in China and India. 8 If cure rates of MDR-TB do not increase than the appearance of extensively drug resistant (XDR-TB) cases will increase greatly. 8 Studies of drug resistance increases the efficiency of detection and can generate new targets for drug development. 9 MDR-TB is recognized as an emerging problem in Nigeria in which 8% of diagnosed cases were MDR-TB, and it is strongly associated with previous treatment. 10 Kazakhstan is one of 14 nations having high morbidity to MDR-TB with resistance to isoniazid and rifampicin. 11 In 2006 the World Health Organization estimated that nearly 500,000 cases of MDR-TB occurred with new cases of XDR-TB (a MDR-TB instance that is also resistant to a fluoroquinolone and at least one second line agent) reported in 45 nations on all five continents. 12 High rates of XDR-TB was reportedly observed in India. 13 From the time period of 1993 to 2007 there were a reported 83 cases of XDR-TB. 14 Cases of XDR-TB have poor outcomes in treatment, prolong periods of infection, and more limited treatment options, conditions that call for new pharmaceutics and clinical treatment options. 15 Investigations have concluded that the emergence of XDR-TB is also a reflection of poor TB management, making the current state of affairs very alarming. 16 Tuberculosis occurring in the spine is a leading spine pathology in India, which causes paraplegia and progressive deformity. 17 Tuberculosis infections of the spine is the most common extrapulmonary form in the Asian subcontinent. 18 Clearly novel drug designs are advised and urgently necessary in order to confront the onslaught of tuberculosis, inclusive of the MDR-TB and XDR-TB cases. The modification of the fundamental isoniazid scaffold has been shown previously to generate potent and usable anti-tuberculosis agents. 19 The modification of known, effective, and established drugs can be an effective approach for rational drug design. 19 This study presents an approach for structure directed drug design to produce hydrazide agents that will have beneficial molecular properties for the clinical treatment of tuberculosis.
Materials and Methods
Molecular modeling and assembly of constructs 
Pattern recognition and elucidation
To identify underlying associations and patterns within the molecular descriptors, such a multivariate numerical data matrix is examined by appropriate pattern recognition techniques. Included in this analytical operation is hierarchical cluster analysis, which was accomplished by and available through KyPlot v. 2.0 Beta 15 (copyright Koichi Yoshioka 1997-2001). Other efficacious pattern recognition methods for elucidation of numerical relationships include discriminant analysis and ANOSIM (analysis of similarity), both of which were performed and available by PAST v. 
Results
Implementing a data mining operation for search of similar substituents (see Materials and Methods) ultimately resulted in 17 constructs presented in Figure 1 Figure 2 . This outcome using Euclidean distance (linear direct distance between two points) and single linkage conditions (the minimum distance between elements of each cluster). Discriminant function analysis is used to classify with the results shown having two groups whose members are determined to be most analogous from properties (variables) presented in Table 1 . The two groups are as follows: i) agent 1 (isoniazid), 3, 4, 7, 8, 11, 12, 13, 14, and 17 ; ii) agent 2, 5, 6, 9, 10, 15, 16, and 18. An additional important relationship that is shown in Figure 3 within formula weight and partition coefficient Log P is a general increase of Log P numerical values with greater formula weight. Substituent data mining incurs an increase of Log P as formula weight varies from low to high.
Discussion
Estimated that one-third of the world's population is infected with TB 3 with infections of other organs in addition to pulmonary infections emphasizes the requisite for alternate drug moieties having focused physiological application. Expressed otherwise, the state of global infection compels the development of additional drug designs having versatile or commodious pharmacodynamics. The contriving of novel constructs initiating from previous effective drug structures is a common methodology for achieving rational drug design. Isoniazid, or pyridine-4-carbohydrazide, is a first-line anti-tuberculosis medication utilized in prevention and treatment of TB. Isoniazid achieves MIC60 of Mycobacterium tuberculosis at concentrations less than 40 μg/mL. 19 Contriving additional drug scaffolds that are modeled following after isoniazid should produce potentially effective clinical tuberculostats. Previous studies have demonstrated the substantial effectiveness of polar surface area (PSA) for prediction of drug transport mediated by intestinal absorption by modeling established drug-like agents properties. 20 Specifically the greater the PSA will inhibit intestinal absorption of an orally administered drug. Namely a PSA greater than 110 A 2 (A= angstroms) suggests an intestinal absorption of less than 20% of total amount of drug present. 20 The PSA values vary from 55.121 A 2 to 94.036 A 2 for expected intestinal absorption that varies from >85% to approximately 35%, respectively. To evaluate druglikeness better and extend profiling methods to lead-like properties of compounds, to achieve better starting points in early drug discovery and for saving of time and cost, the Rule of 5 was introduced. 21 In general an orally active drug has no more than one violation of the following criteria: 21 i) not greater than 5 hydrogen bond donors (i.e. -OH, -NHn); ii) not more than 10 hydrogen bond acceptors (oxygen and nitrogen atoms); iii) a formula weight not greater than 500; and 4) Log P not greater than 5. All 18 agents presented here have zero violations of Rule of 5, thereby indicating favorable druglikeness and bioavailability. Previous studies of oral absorption and brain penetration related to and as a function of polar molecular surface area have shown brain penetration decreases with increasing polar surface area. 22 Orally active drugs which are transported passively through the transcellular route should not exceed a PSA of approximately 120 A 2 . 22 Polar surface area is a dominating factor for oral absorption and brain penetration of drugs which are transported particularly by the transcellular route. 22 Drugs having greatest potential for brain penetration will have a polar surface area of 60 to 70 A 2 . 22 This criteria is met by agents 1 (isoniazid), 2, 3, 5, 6, 7, 8, and 17; which thereby would be useful in the treatment of Mycobacterium tuberculosis infections of the central nervous system. The purpose of cluster analysis is to discover a system of organizing objects, into groups in which members within any group possess similarity in properties. 23 Presented in Figure 2 are these drug agents (denoted as Objects) which are clustered (grouped) according to greatest similarity to other agents. Super node A is the initial parent cluster followed by node B having agents 16, 18, and 17 (most similar). Super node C contains isoniazid (1) with closest drug 6, 7, and 8, followed by 2 and 3. Analysis of similarities (ANOSIM) provides a way to test statistically whether there is a significant difference between two or more groups of sampling units (drugs). 24 A large positive R (up to 1) signifies dissimilarity between groups. Using properties shown in Table 1 the ANOSIM result R=0.2315, indicates an appreciable level of similarity among these compounds, a conclusion expected due to the application of isoniazid as the search parameter within the in silico substituent mining. Discriminant function analysis utilizes differentiating variables to classify two or more naturally occurring groups. 23 The end result of this type of analysis is a model that allows prediction of group membership when only the interval variables are known. 23 Again the two groups are as follows: i) agent 1 (isoniazid), 3, 4, 7, 8, 11, 12, 13, 14, and 17 ; ii) agent 2, 5, 6, 9, 10, 15, 16, and 18. Although somewhat different than the results of hierarchical cluster analysis, the outcome illuminates the compounds most like isoniazid, therefore expected to have similar pharmacodynamics.Note that another relationship exists that is shown in Figure 3 , that formula weight and partition coefficient Log P is generally increasing in Log P values along with greater formula weight. This line is defined by equation: y = 447Ln(x) -2317, having a correlation of polynomial fit to be r = 0.66. Even so the variation in partition coefficient Log P that follows concurrent variation of formula weight brings about modified but efficacious tuberculostatic pharmaceutics varying in routes of administration and permeability in cell membranes which could enhance efficacy of clinical treatment. 19, 21 Potentially the improvement of pharmacokinetics offset the impact of drug resistant Mycobacterium tuberculosis morbidity and mortality. In general the purpose of multiple regression is to learn more about the relationship between several independent or predictor variables and a dependent or criterion variable. Investigators will apply multiple regression when trying to predict some outcome or criterion variable. The premise of multiple regression is similar to that of simple linear regression, however, in multiple regression, interest lies in more than one predictor of our criterion variable. Applying the properties found in Table 1 
